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PXPEDITED REVIEWS
he Reduction of Inflammatory Biomarkers
y Statin, Fibrate, and Combination Therapy
mong Diabetic Patients With Mixed Dyslipidemia
he DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study
oseph B. Muhlestein, MD, FACC,*† Heidi T. May, MSPH,* Jonathan R. Jensen, BS,*
enjamin D. Horne, PHD, MPH,* Richard B. Lanman, MD,‡ Farangis Lavasani, FNP,*
obert L. Wolfert, PHD,‡ Robert R. Pearson, BS,* H. Daniel Yannicelli, MD,§
effrey L. Anderson, MD, FACC*†
alt Lake City, Utah; San Francisco, California; and Abbott Park, Illinois
OBJECTIVES The primary objective was to determine the effect of statin-fibrate combination therapy on
inflammatory biomarkers in patients with diabetes.
BACKGROUND Atherosclerosis is a long-term, chronic inflammatory disease that is exacerbated in patients
with diabetes.
METHODS Patients (n  300) with type II diabetes, mixed dyslipidemia (2 or more of low-density
lipoprotein 100 mg/dl, triglycerides 200 mg/dl, or high-density lipoprotein 40 mg/dl),
and no history of coronary heart disease were randomly assigned to receive simvastatin 20 mg,
fenofibrate 160 mg, or a combination of simvastatin 20 mg and fenofibrate 160 mg daily. At
12 weeks after randomization, we measured levels of high-sensitivity C-reactive protein
(hsCRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2).
RESULTS At 12 weeks, median hsCRP was significantly reduced (14.6%, p  0.004) from baseline,
but the effect did not differ between treatments. The effect was greatest among patients with
baseline hsCRP levels 2.0 mg/l (fenofibrate  18.9%, p  0.002 vs. baseline; simvastatin 
24.8%, p 0.0001; combination27.3%, p 0.002). Likewise, median Lp-PLA2 levels in
the overall study population were significantly reduced (16.8%, p  0.0001), and the effect did
not differ among treatments. This effect also was greatest among patients with increased baseline
levels of Lp-PLA2 greater than the median of 320.9 ng/ml (fenofibrate  41.3%, p  0.0001;
simvastatin  47.5%, p  0.0001; combination  46.8%, p  0.0001).
CONCLUSIONS Simvastatin, fenofibrate, and combination therapy each lowered hsCRP and Lp-PLA2. These
anti-inflammatory effects were most pronounced among patients with increased baseline
levels. Combination therapy was no more effective than either form of monotherapy. (The
DIACOR Study; http://www.clinicaltrials.gov/ct/show/NCT00309712?order1) (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.05.009Coll Cardiol 2006;48:396–401) © 2006 by the American College of Cardiology Foundation
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aiabetes mellitus confers a 2- to 4-fold increase in cardio-
ascular risk compared with the general population (1).
lthough microvascular complications of diabetes result in
ncreased rates of morbidity, macrovascular complications,
ncluding coronary artery disease, often cause death (2).
ardiovascular disease and diabetes are both associated with
levated levels of inflammatory biomarkers, including
-reactive protein (CRP) (3). C-reactive protein is the most
ell-studied inflammatory marker of atherothrombotic risk
4) and is incremental to the Framingham Risk Score (5).
ipoprotein-associated phospholipase A2 (Lp-PLA2) is a
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ccepted April 23, 2006.ewer inflammatory biomarker that has been proposed to be
ore specific to vascular inflammation.
Statin and fibrate therapy have been shown to variably
ower levels of CRP (6,7), as well as levels of Lp-PLA2 (8).
owever, the influence of a statin and fibrate combination
n levels of inflammatory markers requires further investi-
ation (9,10). Therefore, among patients with type II
iabetes, we assessed the effect of statin, fibrate, and
ombination therapy on inflammatory biomarkers in the
IACOR (Diabetes and Combined Lipid Therapy Regi-
en) study.
ETHODS
atients. Patients with a clinical diagnosis of type II
iabetes mellitus and biochemical evidence of mixed dys-
ipidemia were considered for enrollment in the study. The
tudy protocol was approved by the institutional review board,
nd all patients provided written informed consent. Patients
eeting prescreening criteria were required to undergo wash-
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July 18, 2006:396–401 Combination Therapy and Inflammatory Biomarkersut if currently receiving lipid therapy. A complete list of
nclusion/exclusion criteria is found in Table 1.
rotocol. We undertook a single-center, randomized,
ouble-blind, and placebo-controlled 12-week study. Those
articipants satisfying all inclusion/exclusion criteria were
ssigned randomly to receive 1 of 3 daily oral treatments:
imvastatin 20 mg taken in the evening/fenofibrate placebo
aken in the morning with food, fenofibrate 160 mg taking in
he morning with food/simvastatin placebo taken in the
able 1. Inclusion and Exclusion Criteria
Inclusion Criteria
ontrolled type II diabetes mellitus (hemoglobin A1C 9%) Plasma
f taking chronic hypoglycemic therapy including pioglitazone,
rosiglitazone, metformin, sulfonlylureas, or insulin, alone or
in combination, must be on a stable dosing regimen for the
previous 3 months
Known
diseas
or asp
f taking warfarin or warfarin-like anticoagulants, agree to
have their anticoagulation levels drawn per standard of care
for adjustment of anticoagulant dose
History
ocumented post-washout dyslipidemia, defined as having at
least two of the following: LDL 100 mg/dl, triglycerides
200 mg/dl, HDL 40 mg/dl
The use
oil, ni
rando
ble to give voluntary informed consent Serum c
creati
Uncontr
pressu
Proteinu
Hypoth
Concom
or cla
or con
Known
hepat
Partial i
Treatme
Current
Type I d
types
Hyperlip
Any the
comp
Pregnan
Abbreviations and Acronyms
CRP  C-reactive protein
HDL-C  high-density lipoprotein cholesterol
hsCRP  high-sensitivity C-reactive protein
LDL-C  low-density lipoprotein cholesterol
Lp-PLA2  lipoprotein-associated phospholipase A2acceptablevening, or simvastatin 20 mg taken in the evening and
enofibrate 160 mg taken in the morning with food. Coordi-
ators, investigators, statistical personnel, and patients re-
ained blinded to patient treatment assignment.
Follow-up visits were scheduled 6 and 12 weeks after
andomization, where assessment of adverse events and
2-h fasting laboratory measurements were made. A crea-
ine kinase was drawn if the patient complained of any
uscle aches at those visits or at any time throughout the
tudy period.
aboratory measurements. Laboratory samples were ana-
yzed in an Intermountain Healthcare laboratory (LDS
ospital, Salt Lake City, Utah, or McKay Dee Hospital,
gden, Utah). Total cholesterol and triglycerides were
uantified using dry-slide measurement on the VITROS
50 Analyzer (Ortho Clinical Diagnostics, Raritan, New
ersey). High-density lipoprotein cholesterol (HDL-C) was
Exclusion Criteria
ne kinase levels 50% above the upper limit of normal (ULN)
y of coronary heart disease; myopathy, or rhabdomyolysis; active liver
sitive antibodies to hepatitis B or C) or serum alanine aminotransferase
aminotransferase levels 30% above the ULN
ohol consumption: 2 drinks/day or 10 drinks/week
id-lowering agents taken within 6 (bile acid sequestrants, statins, fish
ic acid [doses 200 mg/day], or niacin) or 8 (fibrates) weeks prior to
ion assessment
ine 1.5 mg/dl (if between 1.2 and 1.49 mg/dl, the calculated
learance using the Crockcroft/Gault formula has to be 50 ml/min)
hypertension (systolic blood pressure 160 mm Hg or diastolic blood
100 mm Hg)
ipstick 1 or nephrotic syndrome)
sm (thyroid-stimulating hormone 6 U/ml)
use of cyclosporine, systemic itraconazole or ketoconazole, erythromycin
mycin, nefazadone, HIV protease inhibitors, glucocorticoids, verapamil,
tion of 1 quart of grapefruit juice per day
sensitivity to statins or fibrates (elevated muscle or liver test, jaundice,
ity, or myopathy)
ypass
th any other investigational drug within the previous 30 days
g illicit drugs or history of drug or alcohol abuse within the last 5 years
es mellitus or diagnosis of homozygous familial hypercholesterolemia or
hyperlipidemia
ic pancreatitis, or known presence of cholelithiasis
r condition that would pose a risk to the patient or make it difficult to
h study requirements
/or lactating women and women of child bearing potential not usingcreati
histor
e (po
artate
of alc
of lip
cotin
mizat
reatin
nine c
olled
re 
ria (d
yroidi
itant
rithro
sump
hyper
otoxic
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Combination Therapy and Inflammatory Biomarkers July 18, 2006:396–401easured with the same instrument after treatment with
ITROS HDL-Cholesterol Magnetic Reagent (Ortho
linical Diagnostics); low-density lipoprotein cholesterol
LDL-C) was calculated from the total cholesterol and
riglyceride measurements.
The concentration of high-sensitivity C-reactive protein
hsCRP) was determined using an immunoturbidimetric
ssay on the Hitachi 917 analyzer (Roche Diagnostics,
ndianapolis, Indiana), using reagents and calibrators from
enka Seiken (Niigata, Japan). This assay has a sensitivity
f 0.03 mg/l. The day-to-day variability of the assay at
oncentrations of 0.91 mg/l, 3.07 mg/l, and 13.38 mg/l are
.81%, 1.61%, and 1.1%, respectively. Any patient with an
sCRP 10 mg/l was excluded from the analysis. We
easured Lp-PLA2 by using the PLAC test (diaDexus,
nc., San Francisco, California), and testing was performed
t diaDexus, Inc., as described in the package insert, a
odification of the originally published protocol (11).
Table 2. Characteristics Overall and Among T
Variable
Overall
(n  300)
Gender (male) 55.0%
Age (yrs) 60.6
History of CVA 4.0%
History of PVD 3.3%
Family history of CAD 24.3%
Taking warfarin 5.7%
Hypertension 73.0%
Control diabetes through
Diet 15.7%
Oral antidiabetic agents 87.0%
Insulin 10.7%
Wash off lipid medication 68.3%
Wash off a statin 57.7%
Wash off a fibrate* 11.0%
Wash off a niacin 1.7%
Taking a diuretic 21.6%
Taking beta-blocker 13.8%
Taking an ACE inhibitor 38.7%
Taking thiazolidinediones 32.3%
Taking sulfonylureas 19.7%
Taking metformin at baseline 46.5%
ACE  angiotensin-converting enzyme; CAD  coronary a
vascular disease.
able 3. High-Sensitivity C-Reactive Protein (hsCRP) (mg/l), L
ipid (mg/dl) Levels at Baseline and 12 Weeks Post-Baseline, an
Parameter
Fenofibrate
Baseline
12
Weeks
%
Change
p
Value Baseline
sCRP* 1.99 1.45 14.1 0.17 2.10
p-PLA2* 324.8 245.1 26.9 0.001 313.6
otal cholesterol 226.2 196.1 1.2 0.001 229.3
DL-C 135.4 121.7 5.6 0.001 141.3
DL-C 36.7 41.6 13.7 0.001 37.1
riglycerides* 270.5 154.5 38.2 0.001 230.0
on–HDL-C 188.1 153.6 16.1 0.001 193.4he p values represent a comparison between baseline and 12-week levels within each trea
HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotein chotatistical analysis. This study was designed to provide an
0% power to detect a 20% difference in achievement of the
rimary study end point (percent of patients achieving
riglyceride levels of 200 mg/dl after 12 weeks of treat-
ent, which results are not described here) among study
reatments with 100 patients in each group. Analysis was
erformed blinded by assigning each patient a letter (A, B,
r C) that corresponded to their treatment group using the
ntention-to-treat model. Descriptive statistics were used to
ummarize characteristics of the study population and bio-
arker measurements. For evaluations of concentrations of
riglycerides, hsCRP, and Lp-PLA2, these variables were
ransformed using the natural logarithm to normalize the
istributions before within-group analyses. Differences in
aseline and 12-week levels were evaluated using the paired
test. The effect of study therapy on mean percent reduction
rom baseline levels of lipids, hsCRP, and Lp-PLA2 was
nalyzed using analysis of variance and the Tukey’s HSD
ents at Study Baseline (*p  0.05)
enofibrate
(n  100)
Simvastatin
(n  100)
Combined
(n  100)
48.0% 59.0% 58.0%
61.5 61.4 58.8
3.0% 4.0% 5.0%
3.0% 3.0% 4.0%
24.0% 24.0% 25.0%
3.0% 6.0% 8.0%
73.0% 69.0% 77.0%
17.2% 14.0% 16.0%
86.0% 87.0% 88.0%
12.0% 7.0% 13.0%
76.0% 63.0% 66.0%
63.0% 58.0% 52.0%
16.0% 2.0% 15.0%
3.0% 1.0% 1.0%
25.0% 13.3% 25.6%
15.6% 9.6% 15.6%
37.5% 38.6% 40.0%
27.1% 31.3% 38.9%
16.7% 24.1% 18.9%
45.8% 47.0% 46.7%
isease; CVA  cerebrovascular accident; PVD  peripheral
otein-Associated Phospholipase A2 (Lp-PLA2) (ng/ml), and
rcent Change at 12 Weeks
Simvastatin Combined
12
eeks
%
Change
p
Value Baseline
12
Weeks
%
Change
p
Value
1.80 16.0 0.04 2.24 2.12 15.9 0.10
1.2 34.5 0.001 331.3 217.5 36.2 0.001
9.1 26.2 0.001 230.7 165.2 27.1 0.001
2.0 34.1 0.001 136.9 92.0 29.1 0.001
9.3 7.4 0.001 36.1 40.0 13.0 0.001
2.5 24.8 0.001 284.0 138.0 49.4 0.001
9.8 32.5 0.001 195.0 124.7 34.3 0.001reatm
Fipopr
d Pe
W
22
16
9
3
18
12tment. *Median levels reported due non-normal distribution of the data.
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July 18, 2006:396–401 Combination Therapy and Inflammatory Biomarkersest. Pearson’s correlation coefficient was used to determine
orrelations among percent change at 12 weeks for hsCRP,
p-PLA2, and individual lipid parameters. Two-tailed
values are presented, with 0.05 designated as nominally
ignificant.
ESULTS
able 2 summarizes the baseline characteristics of the
verall study population (n  300) and also among each
reatment group. Overall, significant changes between base-
ine and 12 weeks were found in median levels of hsCRP:
.11 and 1.81 mg/l (14.6%, p  0.004); of Lp-PLA2:
20.9 and 229.4 ng/ml (33.2%, p  0.0001); of triglyc-
rides: 260.0 and 160.0 mg/dl (36.2%, p  0.0001); in
ean levels of total cholesterol: 228.7 and 176.9 mg/dl
21.6%, p  0.0001); of LDL-C: 137.9 and 101.9 mg/dl
23.2%, p  0.0001); of HDL-C: 36.6 and 40.3 mg/dl
11.3%, p  0.0001); and of non–HDL-C: 192.1 and
36.2 (27.6%, p  0.0001), respectively. Table 3 shows
evels of hsCRP, Lp-PLA2, and lipids at baseline and 12
eeks with their percent change by treatment group. Table
 displays comparisons of absolute changes among treat-
ent groups for their ability to modify lipids, hsCRP, and
p-PLA2. No significant difference in effect on either
nflammatory marker was noted between treatment groups.
or those missing 12-week information (n  10), analysis
sing 6-week information was performed and did not alter
he results.
For those with increased levels of baseline hsCRP (2.0
g/l, n  141), the median percent change within each
reatment arm was greater and highly significant (Fig. 1).
or these patients, median hsCRP levels within each
reatment at baseline and 12 weeks were fenofibrate  4.05
nd 2.79 mg/l, simvastatin  3.88 and 2.83 mg/l, and
ombination  3.98 and 2.93 mg/l, respectively. Likewise,
he percent reduction of Lp-PLA2 was greatest among
hose with baseline levels greater than the median of 320.9
n  137) (Fig. 2). For patients with Lp-PLA2 greater than
he median, median levels at baseline and 12 weeks were
enofibrate  459.3 and 237.9 ng/ml, simvastatin  434.9
nd 231.9 ng/ml, and combined  439.1 and 228.2 ng/ml,
espectively.
able 4. Statistical Comparisons (p Values) Among Treatment
roups in the Medications’ Ability to Modify Lipids,
igh-Sensitivity C-Reactive Protein (hsCRP) (mg/l), and
ipoprotein-Associated Phospholipase A2 (Lp-PLA2) (ng/ml)
Parameter F vs. S F vs. C S vs. C
sCRP 0.99 0.99 0.96
p-PLA2 0.93 0.88 0.99
otal cholesterol 0.0001 0.0001 0.64
DL-C 0.0001 0.0001 0.61
on–HDL-C 0.0001 0.0001 0.46
DL-C 0.15 0.84 0.41
riglycerides 0.001 0.07 0.0001f
(
 combined fenofibrate and simvastatin; F  fenofibrate; S  simvastatin; other
bbreviations as in Table 3.The percent change of hsCRP was not correlated with
he percent change of Lp-PLA2 or any lipids. A decrease in
p-PLA2 was significantly correlated with a decrease in
otal cholesterol (r  0.46, p  0.001), LDL-C (r  0.35,
 0.001), and non–HDL-C (r  0.45, p  0.001) with
imvastatin but not with fenofibrate or combination therapy
igure 1. Comparison within each treatment for the median percent change
rom baseline to 12 weeks in high-sensitivity C-reactive protein (hsCRP)
verall (open bars) and for those 2.0 mg/l (solid bars) (n  141).
igure 2. Comparison within each treatment for the median percent change
rom baseline to 12 weeks in lipoprotein-associated phospholipase A2 overall
open bars) and for those 320.9 ng/ml (solid bars).
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Combination Therapy and Inflammatory Biomarkers July 18, 2006:396–401Fig. 3). No other treatments correlated significantly with
nflammatory markers and lipids.
Clinical adverse events were similar among all treatment
roups. There were no cases of rhabdomyolysis, clinical
yopathy (creatine kinase 10 upper limit of control),
ersistent myalgias, or adverse liver-related events, even
mong those subjects who dropped out of the study
n  19). No serious drug-related clinical adverse events
ere noted throughout the study.
ISCUSSION
n this double-blind, placebo-controlled randomized study
f 300 dyslipidemic patients with type II diabetes, we
bserved highly significant modifications in plasma concen-
rations of Lp-PLA2, total cholesterol, LDL-C, HDL-C,
riglycerides, and non–HDL-C in addition to a trend
oward reduction of hsCRP by the combination therapy of
igure 3. Scatter plots showing correlations between change in total choles
reatment group (A  fenofibrate; B  simvastatin; C  combined).imvastatin and fenofibrate. Combination therapy was not Tore effective in modifying levels of hsCRP and Lp-PLA2
han either simvastatin or fenofibrate monotherapy; how-
ver, it was superior in reducing total cholesterol, LDL-C,
nd non–HDL-C concentrations compared with feno-
brate and in reducing triglyceride levels compared with
imvastatin.
Four points contribute to the clinical relevance and
mportance of this study. 1) The magnitude of reduction by
enofibrate, simvastatin, and combination therapy was
reatest when concentrations of hsCRP and Lp-PLA2 were
ncreased 2.0 mg/l and the median value of 320.9 ng/ml,
espectively. 2) The ability of fenofibrate to lower hsCRP
as comparable with simvastatin and combination therapy.
) Reductions of hsCRP were not correlated with any other
ipid parameter or Lp-PLA2 by any treatment. 4) Reduction
f Lp-PLA2 was significantly correlated with reductions in
otal cholesterol, LDL-C, and non–HDL-C by simvastatin.
nd change in lipoprotein-associated phospholipase A2 (LpPLA2) for eachterol ahe extent of correlation to the reduction of LDL is similar
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July 18, 2006:396–401 Combination Therapy and Inflammatory Biomarkerso that reported by Albert et al. (12) in the PRINCE (Effect
f Statin Therapy on C-Reactive Protein Levels: The
ravastatin Inflammation/CRP Evaluation) study.
The important reported relationship between hyperlipid-
mia, chronic inflammation, and cardiovascular risk, as
emonstrated by the strong association among concomitant
eductions in lipids (LDL-C to 70 mg/dl) and inflamma-
ory markers (hsCRP to 2 mg/l) and cardiovascular risk
13), deserves further investigation, as also does the poten-
ially vascular specific inflammatory marker and direct
ascular toxin Lp-PLA2. Little is known regarding the
ffect of combination therapy on inflammatory biomarkers,
ncluding hsCRP, but particularly for Lp-PLA2. Koh et al.
9) examined the effect of atorvastatin, fenofibrate, and the
ombination of atorvastatin and fenofibrate on hsCRP in
atients with hyperlipidemia. Our study, as well as the study
y Koh et al. (9), found all therapies reduced hsCRP levels
rom baseline; however, the magnitude of the reduction was
imilar among all therapies. Our study is the first to report
eductions of Lp-PLA2 by combination therapy. As with
sCRP, all treatments significantly reduced Lp-PLA2 con-
entrations from baseline to 12 weeks, with reductions being
imilar among treatments. Why there was no greater effect
n these inflammatory markers from combination compared
ith either monotherapy is not known. Although statins
nd fibrates have different mechanisms of action in relation-
hip to lipid metabolism, it is possible that they both exert
similar non–dose-responsive effect on inflammation.
herefore, the combination therapy would have no greater
ffect than either monotherapy.
ONCLUSIONS
mong type II diabetic patients with mixed dyslipidemia,
enofibrate, simvastatin, and combination therapy, the use
f each lowered hsCRP and Lp-PLA2. Of interest, combi-
ation therapy was no more effective than either form of
onotherapy. These anti-inflammatory effects were most
ronounced among patients with elevated baseline inflam-
ation levels. Likewise, combination therapy significantlyrting a greater positive combined effect on total cholesterol,
riglycerides, and non–HDL-C than either monotherapy.
eprint requests and correspondence: Dr. J. Brent Muhlestein,
DS Hospital Cardiovascular Department, 8th Avenue and C
treet, Salt Lake City, Utah 84143. E-mail: brent.muhlestein@
ntermountainmail.org.
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